Neuropathological Findings of CSF1R-Related Leukoencephalopathy After Long-Term Immunosuppressive Therapy

Shunsuke Koga; Philip W. Tipton; Klaas J. Wierenga; Dennis W. Dickson; Zbigniew K. Wszolek

doi:10.1002/mds.28919

Neuropathological Findings of CSF1R-Related Leukoencephalopathy After Long-Term Immunosuppressive Therapy

Shunsuke Koga, Philip W. Tipton, Klaas J. Wierenga, Dennis W. Dickson, Zbigniew K. Wszolek

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	439-440
Number of pages	2
Journal	Movement Disorders
Volume	37
Issue number	2
DOIs	https://doi.org/10.1002/mds.28919
State	Published - Feb 2022

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1002/mds.28919

Cite this

@article{1c8eecee373245f79f9bb6d340930d75,

title = "Neuropathological Findings of CSF1R-Related Leukoencephalopathy After Long-Term Immunosuppressive Therapy",

author = "Shunsuke Koga and Tipton, {Philip W.} and Wierenga, {Klaas J.} and Dickson, {Dennis W.} and Wszolek, {Zbigniew K.}",

note = "Funding Information: Z.K.W. is supported by the National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health (1U19AG063911, FAIN: U19AG063911), Mayo Clinic Center for Regenerative Medicine, Mayo Clinic in Florida Focused Research Team Program, gifts from The Sol Goldman Charitable Trust, the Donald G. and Jodi P. Heeringa Family, the Haworth Family Professorship in Neurodegenerative Diseases fund, and The Albertson Parkinson's Research Foundation. He serves as Primary Investigator (PI) or Co‐PI on Biohaven Pharmaceuticals, Inc. (BHV4157‐206 and BHV3241‐301), Neuraly, Inc. (NLY01‐PD‐1), and Vigil Neuroscience, Inc. (VGL101‐01.001) grants. He serves as Co‐PI of the Mayo Clinic APDA Center for Advanced Research and as an external advisory board member for the Vigil Neuroscience, Inc. The other authors report no conflicts of interest. Relevant conflicts of interest/financial disclosures: Funding Information: Dr. Wszolek is partially supported by the National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health (1U19AG063911, FAIN: U19AG063911), Mayo Clinic Center for Regenerative Medicine, Mayo Clinic in Florida Focused Research Team Program, gifts from The Sol Goldman Charitable Trust, the Donald G. and Jodi P. Heeringa Family, the Haworth Family Professorship in Neurodegenerative Diseases fund, and The Albertson Parkinson's Research Foundation. He serves as Primary Investigator (PI) or Co‐PI on Biohaven Pharmaceuticals, Inc. (BHV4157‐206 and BHV3241‐301), Neuraly, Inc. (NLY01‐PD‐1), and Vigil Neuroscience, Inc. (VGL101‐01.001) grants. He serves as Co‐PI of the Mayo Clinic APDA Center for Advanced Research and as an external advisory board member for the Vigil Neuroscience, Inc. The other authors report no conflicts of interest. Funding Information: This study was supported by the Ann B. Smith Research Fund. ",

year = "2022",

month = feb,

doi = "10.1002/mds.28919",

language = "English (US)",

volume = "37",

pages = "439--440",

journal = "Movement Disorders",

issn = "0885-3185",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - Neuropathological Findings of CSF1R-Related Leukoencephalopathy After Long-Term Immunosuppressive Therapy

AU - Koga, Shunsuke

AU - Tipton, Philip W.

AU - Wierenga, Klaas J.

AU - Dickson, Dennis W.

AU - Wszolek, Zbigniew K.

N1 - Funding Information: Z.K.W. is supported by the National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health (1U19AG063911, FAIN: U19AG063911), Mayo Clinic Center for Regenerative Medicine, Mayo Clinic in Florida Focused Research Team Program, gifts from The Sol Goldman Charitable Trust, the Donald G. and Jodi P. Heeringa Family, the Haworth Family Professorship in Neurodegenerative Diseases fund, and The Albertson Parkinson's Research Foundation. He serves as Primary Investigator (PI) or Co‐PI on Biohaven Pharmaceuticals, Inc. (BHV4157‐206 and BHV3241‐301), Neuraly, Inc. (NLY01‐PD‐1), and Vigil Neuroscience, Inc. (VGL101‐01.001) grants. He serves as Co‐PI of the Mayo Clinic APDA Center for Advanced Research and as an external advisory board member for the Vigil Neuroscience, Inc. The other authors report no conflicts of interest. Relevant conflicts of interest/financial disclosures: Funding Information: Dr. Wszolek is partially supported by the National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health (1U19AG063911, FAIN: U19AG063911), Mayo Clinic Center for Regenerative Medicine, Mayo Clinic in Florida Focused Research Team Program, gifts from The Sol Goldman Charitable Trust, the Donald G. and Jodi P. Heeringa Family, the Haworth Family Professorship in Neurodegenerative Diseases fund, and The Albertson Parkinson's Research Foundation. He serves as Primary Investigator (PI) or Co‐PI on Biohaven Pharmaceuticals, Inc. (BHV4157‐206 and BHV3241‐301), Neuraly, Inc. (NLY01‐PD‐1), and Vigil Neuroscience, Inc. (VGL101‐01.001) grants. He serves as Co‐PI of the Mayo Clinic APDA Center for Advanced Research and as an external advisory board member for the Vigil Neuroscience, Inc. The other authors report no conflicts of interest. Funding Information: This study was supported by the Ann B. Smith Research Fund.

PY - 2022/2

Y1 - 2022/2

UR - http://www.scopus.com/inward/record.url?scp=85122925599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122925599&partnerID=8YFLogxK

U2 - 10.1002/mds.28919

DO - 10.1002/mds.28919

M3 - Letter

C2 - 35044689

AN - SCOPUS:85122925599

SN - 0885-3185

VL - 37

SP - 439

EP - 440

JO - Movement Disorders

JF - Movement Disorders

IS - 2

ER -

Neuropathological Findings of CSF1R-Related Leukoencephalopathy After Long-Term Immunosuppressive Therapy

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this